Free Trial

Celularity (CELU) Competitors

Celularity logo
$3.12 -0.16 (-4.88%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$3.13 +0.01 (+0.32%)
As of 08/1/2025 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CELU vs. BNTC, SGMT, AVIR, CRDF, MNPR, UPXI, MREO, LFCR, VOR, and AVTE

Should you be buying Celularity stock or one of its competitors? The main competitors of Celularity include Benitec Biopharma (BNTC), Sagimet Biosciences (SGMT), Atea Pharmaceuticals (AVIR), Cardiff Oncology (CRDF), Monopar Therapeutics (MNPR), Upexi (UPXI), Mereo BioPharma Group (MREO), Lifecore Biomedical (LFCR), Vor Biopharma (VOR), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry.

Celularity vs. Its Competitors

Benitec Biopharma (NASDAQ:BNTC) and Celularity (NASDAQ:CELU) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

52.2% of Benitec Biopharma shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 1.3% of Benitec Biopharma shares are held by insiders. Comparatively, 22.1% of Celularity shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Benitec Biopharma has a net margin of 0.00% compared to Celularity's net margin of -106.77%. Benitec Biopharma's return on equity of -38.26% beat Celularity's return on equity.

Company Net Margins Return on Equity Return on Assets
Benitec BiopharmaN/A -38.26% -35.71%
Celularity -106.77%-271.88%-42.82%

Benitec Biopharma has higher earnings, but lower revenue than Celularity. Benitec Biopharma is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Benitec Biopharma$80K3,596.25-$21.75M-$1.51-7.26
Celularity$54.22M1.38-$57.89M-$2.65-1.18

Benitec Biopharma has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Celularity has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

In the previous week, Celularity had 1 more articles in the media than Benitec Biopharma. MarketBeat recorded 1 mentions for Celularity and 0 mentions for Benitec Biopharma. Benitec Biopharma's average media sentiment score of 1.16 beat Celularity's score of 0.34 indicating that Benitec Biopharma is being referred to more favorably in the media.

Company Overall Sentiment
Benitec Biopharma Positive
Celularity Neutral

Benitec Biopharma currently has a consensus target price of $26.00, indicating a potential upside of 137.23%. Given Benitec Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Benitec Biopharma is more favorable than Celularity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Benitec Biopharma
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
3.13
Celularity
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Benitec Biopharma beats Celularity on 12 of the 17 factors compared between the two stocks.

Get Celularity News Delivered to You Automatically

Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CELU vs. The Competition

MetricCelularityMED IndustryMedical SectorNASDAQ Exchange
Market Cap$78.55M$2.99B$5.48B$9.54B
Dividend YieldN/A2.43%4.73%4.09%
P/E Ratio-1.1817.7428.8623.83
Price / Sales1.38178.75371.4566.14
Price / CashN/A41.9535.4557.96
Price / Book8.438.508.265.54
Net Income-$57.89M-$55.06M$3.25B$259.28M
7 Day Performance5.41%-3.99%-3.75%-4.67%
1 Month Performance53.69%9.58%4.27%4.37%
1 Year Performance6.85%6.70%25.85%17.91%

Celularity Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CELU
Celularity
0.2161 of 5 stars
$3.12
-4.9%
N/A-1.0%$78.55M$54.22M-1.18220News Coverage
Upcoming Earnings
Analyst Upgrade
BNTC
Benitec Biopharma
1.5817 of 5 stars
$11.18
+1.3%
$26.00
+132.6%
+30.0%$289.80MN/A-7.4020Positive News
SGMT
Sagimet Biosciences
2.9704 of 5 stars
$8.83
-6.2%
$26.60
+201.2%
+137.1%$288.65M$2M-5.028Gap Down
AVIR
Atea Pharmaceuticals
1.6961 of 5 stars
$3.43
+2.1%
$6.00
+74.9%
-4.4%$287.55MN/A-2.0870News Coverage
Upcoming Earnings
CRDF
Cardiff Oncology
1.7998 of 5 stars
$3.91
-8.6%
$11.70
+199.2%
+14.3%$284.73M$680K-4.2520Trending News
Earnings Report
Insider Trade
Options Volume
Analyst Revision
Gap Up
MNPR
Monopar Therapeutics
1.9643 of 5 stars
$46.43
-0.1%
$60.00
+29.2%
+1,074.0%$284.23MN/A-13.3410Upcoming Earnings
UPXI
Upexi
3.7435 of 5 stars
$8.15
+9.0%
$16.00
+96.3%
-32.3%$283.61M$26M0.00130Insider Trade
Gap Down
High Trading Volume
MREO
Mereo BioPharma Group
1.3859 of 5 stars
$1.71
-3.4%
$7.20
+321.1%
-58.3%$281.43M$10M-24.4340High Trading Volume
LFCR
Lifecore Biomedical
1.4616 of 5 stars
$7.46
-0.4%
$8.00
+7.2%
+15.9%$277.32M$128.26M-5.14690News Coverage
VOR
Vor Biopharma
0.5983 of 5 stars
$2.05
-7.2%
N/AN/A$276.16MN/A-1.36140News Coverage
Short Interest ↑
Gap Up
AVTE
Aerovate Therapeutics
N/A$9.47
-0.4%
N/A-88.5%$274.49MN/A-3.1720High Trading Volume

Related Companies and Tools


This page (NASDAQ:CELU) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners